TrialPath

Find a study

Match me to a study

241 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicMental healthLungs & breathingHeart & circulationKidney

148 studies on the map

Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder — University of Alabama at Birmingham, BirminghamA Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia — Anaheim Clinical Trials, AnaheimA Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend) — Lighthouse Psychiatry, GilbertStudy of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder — University of Alabama at Birmingham, HuntsvilleA Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder — Harmonex /ID# 277517, DothanA Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH) — Arizona Liver Health, ChandlerA Study to Evaluate the Effectiveness of DT-101 in Patients With Depression — Draig Clinical Site, BentonvilleA Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, OceansidePhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms — University of Alabama at Birmingham, BirminghamA Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. — Pillar Clinical Research /ID# 226504, BentonvilleNBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, ChinoA Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) — 89bio Clinical Study Site, BirminghamA Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease — University of Alabama at Birmingham, BirminghamPCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study — Mood Institute, MilfordBreathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH — Rocky Mountain Regional VA Medical Center, Aurora, CO, AuroraStudy of ALTO-300 in MDD — Site 200, PhoenixE-Mindfulness Approaches for Living After Breast Cancer — Mayo Clinic Hospital in Arizona, PhoenixA Study of LY3971297 in Healthy Participants — CenExel ACT, AnaheimCombination of Novel Therapies for CKD Comorbid Depression — Stony Brook University Medical Center, Stony BrookENA-001 for Opioid Induced Respiratory Depression — South Florida Research Phase I-IV, MiamiModulating Exercise Dosage to Improve Concussion Recovery — University of Colorado Denver, AuroraeValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation — GSK Investigational Site, DoralPolypill for Prevention of Cardiomyopathy — UT Southwestern Medical Center, DallasImpact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD) — Cincinnati Children's Hospital Medical Center, CincinnatiEvaluating the Pharmacokinetics and Safety of Miricorilant — Site# 433, San AntonioEvaluation of Miricorilant on Liver Fat in Patients With MASLD — University of Missouri, ColumbiaBicalutamide Therapy in Young Women With NAFLD and PCOS — University of California San Francisco, San FranciscoMechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease — Ann & Robert H Lurie Children's Hospital of Chicago, ChicagoEstrogen Administration for the Treatment of NASH in Postmenopausal Women — Massachusetts General Hospital, BostonThyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans — Harry S. Truman Memorial, Columbia, MO, ColumbiaMilk Thistle Clinical Trial in Pediatric NAFLD — University Hospitals Cleveland Medical Center, ClevelandRandomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant — Virginia Commonwealth University, RichmondNon-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES) — National Institutes of Health Clinical Center, BethesdaA Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease — Sarfez Pharmaceuticals, Inc., ViennaEquol and Vascular Function in Women With Chronic Kidney Disease — University of Colorado Anschutz Medical Campus, Aurora: Vascular Function in Health and Disease — George E Wahlen VA Medical Center, Salt Lake CityKetamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression — VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann ArborHyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease — University of Kansas Medical Center, Kansas CityInhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia — Duke Asthma Allergy and Airway Center, DurhamHyper Polarized Xenon-129 MRI vs Xenon-133 Scintigraphy — University of Virginia Health System, CharlottesvillePulmonary Hypertension SOLAR — Duke University Medical Center, DurhamThe Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome) — UCSD Sleep Research, La JollaAcceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality — The University of Texas Health Science Center at Houston, HoustonIntravenous Ketamine for Treatment-Resistant Depression — Mayo Clinic in Rochester, RochesterMechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression — National Institutes of Health Clinical Center, BethesdaAcceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease — Children's Hospital Los Angeles, Los AngelesBehavioral Activation Delivered Via Home-based Telehealth to Improve Functioning in Cardiovascular Disease Patients Recently Discharged From Inpatient Care — Ralph H. Johnson VA Medical Center, Charleston, SC, CharlestonPattern Separation in Major Depressive Disorder — New York State Psychiatric Institute (NYSPI), New YorkKetamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression — Icahn School of Medicine at Mount Sinai, New YorkNeuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder — National Institutes of Health Clinical Center, BethesdaInvestigation to Understand and Optimize Psilocybin — Vail Health Behavioral Health, EdwardsTRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors — The University of Texas M. D. Anderson Cancer Center, HoustonSleep Health in U.S. Marines — San Diego State University, San DiegoNeuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV — Massachusetts General Hospital, BostonLeucine in Midlife Depression — Emory University Hospital, AtlantaFamily Acceptance Project Online (Pilot RCT) — University of Michigan, Ann ArborCombination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer — MD Anderson Cancer Center, HoustonNMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits — Washington University School of Medicine, St LouisCannabis for Palliative Care in Cancer — Anschutz Health Sciences Building, AuroraPsilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer — Ohio State University Comprehensive Cancer Center, Columbus5-HTP and Creatine for Depression R33 Phase — University of Utah Department of Psychiatry, Salt Lake CityKetamine Alcohol (in Treatment-Resistant Depression) — University of Iowa Health Care, Iowa CityModulating Spinal Interoceptive Pathways to Evaluate Their Role and Therapeutic Potential in MDD Symptomatic Domains — Lindner Center of Hope, MasonPersonalized Ultrasonic Brain Stimulation for Depression (R61) — University of Utah, Salt Lake CityNebulized Ketamine for the Treatment of Major Depressive Disorder — Maimonides Medical Center, BrooklynBezafibrateTreatment for Bipolar Depression: A Proof of Concept Study — The Dauten Family Center for Bipolar Treatment Innovation at Massachusetts General Hospital, BostonA Digital Intervention for Post-Stroke Depression and Executive Dysfunction — Weill Cornell Medical Center, New YorkPsilocybin Therapy for Depression in Parkinson's Disease — University of California, San Francisco, San FranciscoA New Intervention to Improve Function in Veterans With Anxiety and Depression — Durham VA Medical Center, Durham, NC, DurhamCognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab — Massachusetts General Hospital, BostonEASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease — Pinnacle Research Group, LLC, AnnistonA Ketamine-assisted Group Therapy Intervention for Spanish-speaking Adults With Depression — Massachusetts General Hospital, Chelsea, ChelseaPET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD) — National Institutes of Health Clinical Center, BethesdaThe Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects — VA Connecticut Healthcare System, West HavenA Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH — GSK Investigational Site, ArcadiaA Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH — 89bio Clinical Study Site, BirminghamJAK Signaling in Depression — Emory University, AtlantaA Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure — Research Site, FairhopeOpen-Label Psilocybin Study in Transdiagnostic Population — Connecticut Mental Health Center - Yale School of Medicine, New HavenNeurobiology of Suicide — National Institutes of Health Clinical Center, BethesdaA Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH — Akero Clinical Study Site, BirminghamLIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis — The Institute for Liver Health II DBA Arizona Clinical Trials, PeoriaA Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition — Arizona Liver Health, ChandlerRegulation of Affect and Physiology in Depression — University of Southern California, Los AngelesA Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis — Akero Clinical Study Site, BirminghamPsilocybin in Chronic Low Back Pain and Depression — Johns Hopkins University School of Medicine, BaltimoreStudy of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans — Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine,, West HavenInvestigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression — National Institutes of Health Clinical Center, BethesdaA Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH — GSK Investigational Site, ArcadiaPsilocybin to Treat Depression in Spinal Cord Injury — James J. Peters Department of Veterans Affairs Medical Center, The BronxLIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis — University of Alabama at Birmingham, BirminghamTraining Reward Responsiveness Through Virtual Reality — University of California, Los Angeles, Los Angeles[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET — National Institutes of Health Clinical Center, BethesdaA Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. — Research Site, SurpriseNeutralizing Interleukin (IL)-6 — Icahn School of Medicine at Mount Sinai, New YorkMindfulness-based Psilocybin Therapy for PTSD — The Ohio State University Medical Center, ColumbusCreatine for Depressed Male and Female Methamphetamine Users — Montana State University College of Nursing (Missoula campus), MissoulaPsilocybin rTMS for Treatment Resistant Depression — Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600, AustinComputerized Cognitive Behavioral Therapies for Suicide Prevention and Depression — Eastern Colorado Health Care System, AuroraOrexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial — James J. Peters Veterans Affairs Medical Center, The BronxDepemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2) — GSK Investigational Site, SheffieldA Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA) — Noble Clinical Research, TucsonAlpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response — Yale University, New HavenA Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006) — Research Site, FoleyEfficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype — Chandler Clinical Research Trials- Site Number : 8400025, ChandlerA Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease — Research Site, Birmingham"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" — Scottsdale Research Institute, PhoenixA Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD — SEC Clinical Research, LLC, DothanSlow Wave Induction by Propofol to Eliminate Depression (SWIPED) Stage II — Washington University School of Medicine/Barnes-Jewish Hospital, St LouisGroup Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies — Fred Hutch/University of Washington Cancer Consortium, SeattleA Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007) — Research Site, CullmanA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) — UAB Lung Health Center, BirminghamClemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression — University of Illinois College of Medicine, ChicagoA Study to Evaluate Solrikitug in Participants With COPD (ZION) — University of Alabama at Birmingham Hospital, BirminghamA Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease — Research Site, AthensCannabidiol for Reduction of Brain Neuroinflammation — Massachusetts General Hospital, BostonEvaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression — Laureate Institute for Brain Research, TulsaEfficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype — University of Alabama at Birmingham- Site Number : 8400003, BirminghamA Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease — University of Alabama at Birmingham Lung Health Center, BirminghamRademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD) — University of Alabama at Birmingham Lung Health Center, BirminghamAllopregnanolone (Zuranolone) in Post-stroke Depression — Duke South Neurology Clinic 1L, DurhamPharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation — Mclean Hospital, BelmontThe Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder — Athinoula A. Martinos Center for Biomedical Imaging, CharlestownPrefrontal Glutamatergic Modulation by NAC and MBCT for Depression in Youth — University of Cincinnati, Department of Psychiatry and Behavioral Neuroscience, CincinnatiStratified Pharmacological Approaches for Regulating Circuit-Level Effects — Stanford University, Palo AltoCannabidiol and Older Adult Cannabis Users — University of Colorado at Boulder, BoulderHome-Based Transcranial Direct Current Stimulation (tDCS) for Depression in Multiple Sclerosis (MS) — NYU Langone Health, New YorkMulticenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients — Harmonex Neuroscience Research, DothanA Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder — IMA Clinical Research Phoenix, PhoenixA Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study) — Seaport Investigator Site, ChinoPsilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy — MD Anderson Cancer Center, HoustonA Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder — UAB Psychiatry and Behavioral Neurology, BirminghamA Study of Brenipatide in Adult Participants With Major Depressive Disorder — Accellacare - Moorpark, MoorparkA Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) — Harmonex Neuroscience Research, DothanALTO-207 in Adults With Treatment-resistant Depression (TRD) — Site 7074, BirminghamPramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV — Alabama CRS, BirminghamLong-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, HuntsvilleEvaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder — Vanda Investigational Site, PhoenixLow Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy — Pine Rest Christian Mental Health Services, Grand RapidsA Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH — GSK Investigational Site, ChandlerA Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder — NoesisPharma, LLC, PhoenixA Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH) — Arizona Liver Health - Chandler, ChandlerA Study of Ketamine Infusions to Treat Clinically-depressed ICU Patients — Mayo Clinic Florida, JacksonvilleA Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder — University of Alabama at Birmingham, BirminghamA Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) — Noble Clinical Research, TucsonALTO-100 in Bipolar Disorder With Depression (BD-D) — Site 6036, ChandlerClinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD — University of Alabama, BirminghamACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response — University of Alabama at Birmingham, Birmingham

Showing the 150 nearest — narrow your filters for fewer, closer studies.